Digital Quantification of Gene Expression in Sequential Breast Cancer Biopsies Reveals Activation of an Immune Response

• Rinath M. Jeselsohn,

  Affiliations Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Lillian Werner,

  Affiliation Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Meredith M. Regan,

  Affiliation Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Aquila Fatima,

  Affiliation Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Lauren Gilmore,

  Affiliation Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Laura C. Collins,

  Affiliation Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Andrew H. Beck,

  Affiliation Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Shannon T. Bailey,

  Affiliations Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Housheng Hansen He,

  Affiliations Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Gilles Buchwalter,

  Affiliations Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Myles Brown ,

  * E-mail: myles_brown@dfci.harvard.edu (MB); scome@bidmc.harvard.edu (SEC)

  Affiliations Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• J. Dirk Iglehart,

  Affiliations Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Andrea Richardson,

  Affiliations Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Steven E. Come

  * E-mail: myles_brown@dfci.harvard.edu (MB); scome@bidmc.harvard.edu (SEC)

  Affiliation Breast Medical Oncology Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯